A patient-centred approach to malignant pleural effusion. [PDF]
Shorthose M, Crook R, Bhatnagar R.
europepmc +1 more source
Malignant Chylothorax, a Rare Cause of Bilateral Pleural Effusions [PDF]
Fazal Raziq +4 more
openalex +1 more source
Acute Empyema due to Gemella morbillorum Following COVID‐19 in an Otherwise Healthy Middle‐Aged Man
A previously healthy, non‐elderly man developed acute empyema 3 weeks after COVID‐19 infection, requiring VATS debridement. Gemella morbillorum was isolated from intraoperative specimens, an exceptionally rare pathogen in individuals without predisposing factors.
Kazumasa Nanjo +3 more
wiley +1 more source
The Evolving Role of Medical Thoracoscopy for the Management of Malignant Pleural Effusion. [PDF]
Lovato JB +3 more
europepmc +1 more source
Effusion‐Dominant Pulmonary Sarcomatoid Carcinoma Without a Primary Mass: A Case Report
We describe a patient with high‐grade sarcomatoid carcinoma presenting as malignant pleural effusion without a primary mass. This case highlights the diagnostic challenges, aggressive clinical course, and importance of early biopsy. We also review the limited literature describing similar presentations.
Sze Kye Teoh +5 more
wiley +1 more source
Diagnostic value of pleural fluid neuron-specific enolase for malignant pleural effusion. [PDF]
Lin X +13 more
europepmc +1 more source
The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial [PDF]
Rahul Bhatnagar +6 more
openalex +1 more source
Use of Octreotide in Chylothorax With Mediastinal Mass of Unknown Behaviour: A Case Report
A 37‐year‐old woman with chylothorax and a mediastinal mass of uncertain behaviour had persistent pleural drainage despite initial interventions and unavailable advanced options. Octreotide infusion resulted in a marked reduction of drainage and complete resolution.
Arnold Joseph Geronimo, Manuel Monis
wiley +1 more source

